Grail, a spinout company of the DNA-sequencing giant Illumina, has a very bold mission: to develop a blood-based screening test for cancer. The company is now seeking to raise $1.7 billion, say three ...
BRUSSELS — The European Union on Thursday ordered US biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of ...
Grail’s screening test, called Galleri, could one day help save countless lives by catching cancer in the bloodstream early. But for Illumina, acquiring Grail has only caused it pain. After losing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback